DOABETIC 5mg _ price in UAE

Overview

Welcome to Dwaey, specifically on DOABETIC 5mg _ Tablets page.
This medicine contains an important and useful components, as it consists of Glibenclamide.
DOABETIC 5mg _ is available in the market in concentration 5mg/Tablet and in the form of Tablets.

KUWAIT SAUDI PHARMACEUTICAL INDUSTRIES CO. (KSPICO) is the producer of DOABETIC 5mg _ and it is imported from KUWAIT, The most popular alternatives of DOABETIC 5mg _ are listed downward .

Mode Of Action

Glibenclamide lowers blood glucose concentration principally by stimulating secretion of endogenous insulin from the pancreatic beta-cells. Hypoglycaemic action associated w/ short-term therapy appears to include reduction of basal hepatic glucose production and enhancement of peripheral insulin action at target sites.

Indication

Type 2 DM

Precaution

Elderly; malnourished; mild to moderate renal and hepatic disorders. Impaired alertness. Avoid alcohol. Careful monitoring of blood-glucose concentration. Adrenocortical insufficiency. Changes in diet or prolonged exercise may also provoke hypoglycaemia. Increased risk of hypoglcaemia due to its long half-life. Avoid in severe hepatic impairment. Pregnancy, lactation. Lactation: Not known if crosses into breast milk; avoid use in nursing women

Side Effects

Hypoglycaemia; cholestatic jaundice; agranulocytosis; aplastic anaemia; haemolytic anaemia. Blood dyscrasias (reversible)
liver dysfunction
GI symptoms
allergic skin reactions. Potentially Fatal: Prolonged hypoglycaemia seen in elderly or debilitated patients with hepatic or renal diseases.

Contra indication

Severe or life-threatening hyperglycaemia, severe liver or renal failure, type 1 diabetes, diabetic ketoacidosis with or without coma, patients with severe infection or trauma.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Serum levels may be reduced by colesevelam. May increase hypoglycaemic effect w/ MAOIs, chloramphenicol, fluoroquinolones (e.g. ciprofloxacin), probenecid, NSAIDs, ACE inhibitors, fluoxetine, disopyramide, clarithromycin, salicylates, sulfonamides, beta-blockers. Increased serum levels w/ antifungal antibiotics (e.g. miconazole, fluconazole). May decrease hypoglycaemic effect w/ nonthiazide (e.g. furosemide) and thiazide diuretics, corticosteroids, phenothiazines, thyroid agents, oestrogens, OC, phenytoin, nicotinic acid, sympathomimetic agents, rifampicin, Ca channel blockers, isoniazid. Potentially Fatal: May increase hepatotoxic effect of bosentan.